Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 10/20 | 0.43 |
| ▸ | KDR | P35968 | 6/20 | 0.43 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.43 |
| ▸ | TNNI3K | Q59H18 | 2/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.40 |
| ▸ | FLT3 | P36888 | 1/20 | 0.39 |
| ▸ | NAMPT | P43490 | 1/20 | 0.39 |
| ▸ | BTK | Q06187 | 1/20 | 0.38 |
| ▸ | CIT | O14578 | 1/20 | 0.38 |
| ▸ | CDK8 | P49336 | 1/20 | 0.37 |
| ▸ | FLT1 | P17948 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3696934 | 0.92 | BRAF (0.44) | BRAFKDRMAPK14TNNI3KCYP2D6 | |
| SCHEMBL15053102 | 0.92 | KDR (0.44) | BRAFKDRMAPK14TNNI3K | |
| SCHEMBL15053398 | 0.90 | CYP2D6 (0.50) | BRAFCYP2D6CYP2C9BTKCIT | |
| SCHEMBL15054194 | 0.89 | NTRK1 (0.43) | BRAFKDRFLT3NAMPT | |
| SCHEMBL15053065 | 0.89 | CIT (0.38) | BRAFKDRMAPK14TNNI3KFLT3 | |
| SCHEMBL15053152 | 0.88 | BRAF (0.45) | BRAFKDRMAPK14TNNI3KCYP2D6 | |
| SCHEMBL15053487 | 0.88 | BRAF (0.53) | BRAFKDRMAPK14TNNI3KCYP2D6 | |
| SCHEMBL15053467 | 0.87 | PTGER3 (0.43) | BRAFKDRMAPK14TNNI3KCYP2C9 | |
| SCHEMBL15053289 | 0.86 | AURKA (0.44) | BRAFKDRMAPK14TNNI3KBTK | |
| SCHEMBL15053328 | 0.86 | PTGER3 (0.43) | BRAFKDRCYP2D6CYP2C9FLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130165475-A1 | DEUTERIUM-ENRICHED HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | ASCEPION PHARMACEUTICALS, INC. (CN) | 2013-06-27 | — | — | US | claimed |
| US-20130165475-A1 | DEUTERIUM-ENRICHED HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | ASCEPION PHARMACEUTICALS, INC. (CN) | 2013-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130165475-A1 | DEUTERIUM-ENRICHED HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | CDK2, CDK1, CDK3 | BRAF 90/4885KDR 1965/4885MAPK14 113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.